Niels Behrendt

List of Publications by Year
in descending order

75 papers	4,414 citations	87723 38 h-index	106150 65 g-index
79 all docs	79 docs citations	79 times ranked	4163 citing authors

#	Article	IF	Citations
1	Uncovering mediators of collagen degradation in the tumor microenvironment. Matrix Biology Plus, 2022, 13, 100101.	1.9	17
2	Osteosarcoma and Metastasis Associated Bone Degradationâ€"A Tale of Osteoclast and Malignant Cell Cooperativity. International Journal of Molecular Sciences, 2021, 22, 6865.	1.8	29
3	The Collagen Receptor uPARAP in Malignant Mesothelioma: A Potential Diagnostic Marker and Therapeutic Target. International Journal of Molecular Sciences, 2021, 22, 11452.	1.8	3
4	Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis. Scientific Reports, 2020, 10, 19138.	1.6	12
5	Cellular uptake of collagens and implications for immune cell regulation in disease. Cellular and Molecular Life Sciences, 2020, 77, 3161-3176.	2.4	28
6	The collagen receptor uPARAP/Endo180 regulates collectins through unique structural elements in its FNII domain. Journal of Biological Chemistry, 2020, 295, 9157-9170.	1.6	7
7	CCL2/MCP-1 signaling drives extracellular matrix turnover by diverse macrophage subsets. Matrix Biology Plus, 2019, 1, 100003.	1.9	18
8	Immune regulation by fibroblasts in tissue injury depends on uPARAP-mediated uptake of collectins. Journal of Cell Biology, 2019, 218, 333-349.	2.3	14
9	TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding. JCI Insight, 2019, 4, .	2.3	8
10	Prevention of Bleeding-Induced Vascular Abnormalities in the Hemophilic Mouse Joint By Increasing TAFI Levels or Inhibiting uPA Activity. Blood, 2019, 134, 158-158.	0.6	0
11	uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis. Nature Communications, 2018, 9, 5178.	5.8	19
12	Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding. Blood, 2018, 132, 1593-1603.	0.6	31
13	Phagocytosis of Collagen Fibrils by Fibroblasts In Vivo Is Independent of the uPARAP/Endo180 Receptor. Journal of Cellular Biochemistry, 2017, 118, 1590-1595.	1.2	13
14	Tumor-Associated Macrophages Derived from Circulating Inflammatory Monocytes Degrade Collagen through Cellular Uptake. Cell Reports, 2017, 21, 3662-3671.	2.9	99
15	The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers. Oncotarget, 2017, 8, 44605-44624.	0.8	26
16	Crystal structures of the ligand-binding region of uPARAP: effect of calcium ion binding. Biochemical Journal, 2016, 473, 2359-2368.	1.7	12
17	Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180. Journal of Pathology, 2016, 238, 120-133.	2.1	25
18	The collagen receptor uPARAP/Endo180 in tissue degradation and cancer (Review). International Journal of Oncology, 2015, 47, 1177-1188.	1.4	57

#	Article	IF	Citations
19	Complex Determinants in Specific Members of the Mannose Receptor Family Govern Collagen Endocytosis. Journal of Biological Chemistry, 2014, 289, 7935-7947.	1.6	42
20	Matrix metalloproteinase 2 and membrane type 1 matrix metalloproteinase coâ€regulate axonal outgrowth of mouse retinal ganglion cells. Journal of Neurochemistry, 2014, 129, 966-979.	2.1	28
21	Advances in targeted delivery of small interfering RNA using simple bioconjugates. Expert Opinion on Drug Delivery, 2014, 11, 791-822.	2.4	16
22	M2-like macrophages are responsible for collagen degradation through a mannose receptorâ€"mediated pathway. Journal of Cell Biology, 2013, 202, 951-966.	2.3	269
23	Ficolin-1â€"PTX3 Complex Formation Promotes Clearance of Altered Self-Cells and Modulates IL-8 Production. Journal of Immunology, 2013, 191, 1324-1333.	0.4	68
24	Targeting a Single Function of the Multifunctional Matrix Metalloprotease MT1-MMP. Journal of Biological Chemistry, 2013, 288, 10195-10204.	1.6	55
25	Differential Actions of the Endocytic Collagen Receptor uPARAP/Endo180 and the Collagenase MMP-2 in Bone Homeostasis. PLoS ONE, 2013, 8, e71261.	1.1	25
26	New and Paradoxical Roles of Matrix Metalloproteinases in the Tumor Microenvironment. Frontiers in Pharmacology, 2012, 3, 140.	1.6	88
27	Inhibitory Monoclonal Antibodies against Mouse Proteases Raised in Gene-Deficient Mice Block Proteolytic Functions in vivo. Frontiers in Pharmacology, 2012, 3, 122.	1.6	7
28	Endocytic collagen degradation: a novel mechanism involved in protection against liver fibrosis. Journal of Pathology, 2012, 227, 94-105.	2.1	45
29	A Novel Functional Role of Collagen Glycosylation. Journal of Biological Chemistry, 2011, 286, 32736-32748.	1.6	75
30	Conformational Regulation of Urokinase Receptor Function. Journal of Biological Chemistry, 2011, 286, 33544-33556.	1.6	51
31	The Non-phagocytic Route of Collagen Uptake. Journal of Biological Chemistry, 2011, 286, 26996-27010.	1.6	106
32	Cooperation Between Proteolysis and Endocytosis in Collagen Turnover. , 2011, , 53-74.		3
33	The collagen receptor uPARAP/Endo180. Frontiers in Bioscience - Landmark, 2009, Volume, 2103.	3.0	49
34	MT1-MMP and Type II Collagen Specify Skeletal Stem Cells and Their Bone and Cartilage Progeny. Journal of Bone and Mineral Research, 2009, 24, 1905-1916.	3.1	33
35	Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells. Biological Chemistry, 2008, 389, 943-953.	1.2	29
36	Antibody-mediated Targeting of the Urokinase-type Plasminogen Activator Proteolytic Function Neutralizes Fibrinolysis in Vivo. Journal of Biological Chemistry, 2008, 283, 32506-32515.	1.6	34

#	Article	IF	Citations
37	A Composite Role of Vitronectin and Urokinase in the Modulation of Cell Morphology upon Expression of the Urokinase Receptor. Journal of Biological Chemistry, 2008, 283, 15217-15223.	1.6	26
38	24Specific targeting of uPA activity with a monoclonal antibody neutralizeS uPA-dependent effects â€¨<i>in vivo</i>. Apmis, 2008, 116, 428-428.	0.9	0
39	Extracellular Collagenases and the Endocytic Receptor, Urokinase Plasminogen Activator Receptor-associated Protein/Endo180, Cooperate in Fibroblast-mediated Collagen Degradation. Journal of Biological Chemistry, 2007, 282, 27037-27045.	1.6	119
40	Complementary Roles of Intracellular and Pericellular Collagen Degradation Pathways In Vivo. Molecular and Cellular Biology, 2007, 27, 6309-6322.	1.1	81
41	Increased Expression of the Collagen Internalization Receptor uPARAP/Endo180 in the Stroma of Head and Neck Cancer. Journal of Histochemistry and Cytochemistry, 2007, 55, 347-353.	1.3	53
42	Plasminogen activation and cancer. Thrombosis and Haemostasis, 2005, 93, 676-681.	1.8	398
43	Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. Journal of Cell Biology, 2005, 169, 977-985.	2.3	127
44	The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/ Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. Biological Chemistry, 2004, 385, 103-36.	1.2	86
45	uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV. Experimental Cell Research, 2004, 293, 106-116.	1.2	96
46	uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion. Journal of Cell Biology, 2003, 160, 1009-1015.	2.3	166
47	The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochemical Journal, 2003, 371, 277-287.	1.7	40
48	Urokinase receptor-associated protein (UPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells. International Journal of Cancer, 2002, 98, 656-664.	2.3	57
49	Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene, 2002, 21, 3765-3779.	2.6	300
50	Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochemical Journal, 2001, 358, 673.	1.7	43
51	Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochemical Journal, 2001, 358, 673-679.	1.7	50
52	The Urokinase Plasminogen Activator Receptorâ€"Associated Protein/Endo180 Is Coexpressed with Its Interaction Partners Urokinase Plasminogen Activator Receptor and Matrix Metalloprotease-13 during Osteogenesis. Laboratory Investigation, 2001, 81, 1403-1414.	1.7	62
53	The Urokinase Receptor Associated Protein (uPARAP/Endo180) A Novel Internalization Receptor Connected to the Plasminogen Activation System. Trends in Cardiovascular Medicine, 2001, 11, 7-13.	2.3	43
54	Differential Binding of Urokinase and Peptide Antagonists to the Urokinase Receptor: Evidence from Characterization of the Receptor in Four Primate Species. Biological Chemistry, 2001, 382, 435-42.	1.2	13

#	ARTICLE	IF	CITATIONS
55	A Urokinase Receptor-associated Protein with Specific Collagen Binding Properties. Journal of Biological Chemistry, 2000, 275, 1993-2002.	1.6	134
56	Plasminogen-Independent Initiation of the Pro-urokinase Activation Cascade in Vivo. Activation of Pro-urokinase by Glandular Kallikrein (mGK-6) in Plasminogen-Deficient Mice. Biochemistry, 2000, 39, 508-515.	1.2	44
57	Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology. Journal of Immunological Methods, 1999, 222, 125-133.	0.6	39
58	The urokinase receptor. Fibrinolysis and Proteolysis, 1998, 12, 191-204.	1.1	65
59	Reply to comment on â€˜Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation systemâ€™ (A. A-R. Higazi). FEBS Letters, 1997, 402, 293-294.	1.3	4
60	The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Letters, 1997, 420, 79-85.	1.3	131
61	Cell-Surface Acceleration of Urokinase-Catalyzed Receptor Cleavage. FEBS Journal, 1997, 243, 21-26.	0.2	99
62	ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts. , 1997, 72, 416-423.		15
63	Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system. FEBS Letters, 1996, 393, 31-36.	1.3	17
64	Domain Interplay in the Urokinase Receptor. Journal of Biological Chemistry, 1996, 271, 22885-22894.	1.6	92
65	Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. Journal of Immunological Methods, 1994, 167, 91-101.	0.6	55
66	A novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminase-catalyzed cross-linking. FEBS Letters, 1993, 336, 394-396.	1.3	26
67	[14] Cellular receptor for urokinase-type plasminogen activator: Function in cell-surface proteolysis. Methods in Enzymology, 1993, 223, 223-233.	0.4	25
68	[13] Cellular receptor for urokinase-type plasminogen activator: Protein structure. Methods in Enzymology, 1993, 223, 207-222.	0.4	33
69	Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. FEBS Journal, 1992, 205, 451-458.	0.2	57
70	Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Letters, 1991, 288, 233-236.	1.3	177
71	Protein Structure and Membrane Anchorage of the Cellular Receptor for Urokinase-Type Plasminogen Activator. Seminars in Thrombosis and Hemostasis, 1991, 17, 183-193.	1.5	111
72	The urokinase receptor and regulation of cell surface plasminogen activation. Cell Differentiation and Development, 1990, 32, 247-253.	0.4	57

#	Article	IF	Citations
73	Protein chemical characterization of the cellular receptor for urokinase-type plasminogen activator. Fibrinolysis, 1989, 3, 2.	0.5	2
74	A novel polymorphism of human complement component C3 detected by means of a monoclonal antibody. Immunogenetics, 1986, 23, 322-325.	1.2	19
75	Human complement component C3: Characterization of active C3 S and C3 F, the two common genetic variants. Molecular Immunology, 1985, 22, 1005-1008.	1.0	8